About the ABPI

The ABPI represents innovative resea​rch-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.

Globally our industry is researching and developing more than 7,000 new medicines.

The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.​​​​​​​

*The MISG, co-chaired by the Secretary of State for Health and Social Care and the Chairman of the British Pharma Group, works to promote a strong and profitable UK-based bio-pharmaceutical industry.

804 applications for commercial clinical trials were received by the Medicines and Healthcare products Regulatory Agency (MHRA) in 2016: Clinical trials for medicines: authorisation assessment performance (HM Government, Dec 2017)

Media enquiries


+44 (0) 20 7747 7147​​